Institutional members access full text with Ovid®

Share this article on:

The prohibition of kidney sales and organ markets should remain

Danovitch, Gabriel M; Delmonico, Francis L

Current Opinion in Organ Transplantation: August 2008 - Volume 13 - Issue 4 - p 386–394
doi: 10.1097/MOT.0b013e3283097476
Renal transplantation: Edited by Robert A. Montgomery

Purpose of review There is an ongoing vigorous debate regarding the wisdom of the current prohibition of organ sales in the United States. We argue that this prohibition must remain in place. We discuss the current international realities regarding organ vending in order to show that even a so-called ‘regulated’ market brings with it danger to the welfare of transplant donors, their recipients, and potential recipients of nonrenal organs. We counter the specific arguments made in favor of organ sales while recommending multiple measures that can serve to remove disincentives to noncommercial organ donation. We encourage the investment in innovative healthy transplant practice for the benefit of all.

Recent findings In ‘natural experiments’ performed in developing countries the outcome for kidney vendors, in terms of both their medical and psychosocial health, has been shown to be poor. A high incidence of serious infections has been reported in recipients of vended organs.

Summary Commercialization of living kidney donation does not serve the interests of the donors, endangers the health of recipients, and undermines the healthy development of the international transplant endeavor.

aKidney and Pancreas Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

bHarvard Medical School, Massachusetts General Hospital Transplant Center, Boston, Massachusetts, USA

Correspondence to Gabriel M. Danovitch, David Geffen School of Medicine at UCLA, Los Angeles, California, USA E-mail: gdanovitch@mednet.ucla.edu

Copyright © 2008 Wolters Kluwer Health, Inc. All rights reserved.